DETROIT – Recently, a tiny group of people with rectal cancer saw their disease vanish after experimental treatment. It was a very small trial done by doctors at New York’s Memorial Sloan Kettering Cancer Center, wherein the patients took a drug called dostarlimab for six months. At the end of their trial, every single one of their tumors disappeared.
Now, in another breakthrough, a new compound synthesized by Dr. Jung-Mo Ahn, a University of Texas at Dallas researcher, has been found to kill a broad spectrum of hard-to-treat cancers, including triple-negative breast cancer, leaving healthy cells unscathed.
He exploited a weakness in cells that were hitherto not targeted by the other drugs.
The study, which was carried out in isolated cells, both in human cancer tissue and in human cancers grown in mice, was published in the journal Nature Cancer.
To read more, click on Interesting Engineering
